Blood ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 82 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
Showing 1 to 10 of 82 diseases
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05039216 (ClinicalTrials.gov) | September 13, 2021 | 6/9/2021 | Biobank for Inflammatory Chronic Diseases and Osteoporosis | Biobank for Inflammatory Chronic Diseases and Osteoporosis of TOULouse | Rheumatoid Arthritis;Psoriatic Arthritis;Spondyloarthritis;Osteoporosis | Biological: Blood sampling | University Hospital, Toulouse | NULL | Recruiting | 18 Years | 99 Years | All | 2000 | France | |
| 2 | ITMCTR2100004302 | 2021-01-21 | 2021-01-21 | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | difficult-to-treat rheumatoid arthritis | The normal group:No special treatment;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan; The normal group:No special treatment;Refractory (control group):Methotrexate + folic acid tablets + ... | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University o ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15;Refractory (control group):15;Refractory (trial group):15; Primary untreated group:15;Therapeutic effective group:15; | China | |
| 3 | ChiCTR2100042440 | 2021-01-21 | 2021-01-21 | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis wit ... | difficult-to-treat rheumatoid arthritis | The normal group:No special treatment; Primary untreated group:Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders;Therapeutic effective group:Continue the original treatment plan;Refractory (trial group):Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription;Refractory (control group):Methotrexate + folic acid tablets + adalimumab + simulant; The normal group:No special treatment; Primary untreated group:Do not give any treatment, only befor ... | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University o ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15; Primary untreated group:15;Therapeutic effective group:15;Refractory (trial group):15;Refractory (control group):15; | China | |
| 4 | ChiCTR2100042328 | 2021-01-19 | 2021-01-19 | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Rheumatoid arthritis | The normal group:No special treatment will be given;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow-up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent; The normal group:No special treatment will be given;Primary untreated group:No treatment was given, ... | Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine) Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University ... | NULL | Recruiting | 18 | 70 | Both | The normal group:15;Primary untreated group:15;Therapeutic effective group:15;Observation group:15;The control group:15; | China | |
| 5 | ITMCTR2100004288 | 2021-01-19 | 2021-01-19 | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Effect of Wenyang Tongluo Recipe on Cold Syndrome of Rheumatoid Arthritis and Drug Resistant Gene | Rheumatoid arthritis | Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;Primary untreated group:No treatment was given, only blood was drawn before treatment, and follow-up treatment was not considered in this group. Patients were advised to seek medical treatment by themselves and follow the doctor's advice;Therapeutic effective group:Continue with the original regimen;The control group:Methotrexate + folic acid tablets + adamulizumab + simulation agent;The normal group:No special treatment will be given; Observation group:Methotrexate + folic acid tablets + Adamumab + Wenyang Tongluo Recipient;Primary u ... | Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine) Yunnan Hospital of Traditional Chinese Medicine (The First Affiliated Hospital of Yunnan University ... | NULL | Recruiting | 18 | 70 | Both | Observation group:15;Primary untreated group:15;Therapeutic effective group:15;The control group:15;The normal group:15; | China | |
| 6 | NCT04470453 (ClinicalTrials.gov) | October 8, 2020 | 9/7/2020 | Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concent ... | Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concentration and Clinical Response in Rheumatoid Arthritis Patients Treated With Subcutaneous Injectable Methotrexate and a First Biological Drug Association Between Methotrexate Erythrocyte Polyglutamate Concentration and Biological Drug Concent ... | Rheumatoid Arthritis | Biological: Blood sample;Diagnostic Test: CRQ | Centre Hospitalier Universitaire de Saint Etienne | NULL | Recruiting | 18 Years | N/A | All | 60 | Phase 4 | France |
| 7 | NCT04584541 (ClinicalTrials.gov) | June 11, 2020 | 10/6/2020 | SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism | Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthritis and Spondyloarthritis Under Immunosuppressive Treatments Study of the Viral Load and Humoral and Cellular B and T Responses in Patients With Rheumatoid Arthr ... | Spondyloarthritis;Rheumatoid Arthritis;Covid19 | Biological: blood tests;Biological: Nasopharyngeal swabs;Biological: Stools | Assistance Publique - Hôpitaux de Paris | NULL | Terminated | 18 Years | N/A | All | 150 | N/A | France |
| 8 | EUCTR2019-001554-25-NL (EUCTR) | 29/10/2019 | 29/10/2019 | Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trail Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood(ADDORA): multi ... | Adalimumab dose optimization in rheumatoid arthritis using therapeuticdrug monitoring (ADDORA): multi-center open label randomized controlledtrail - ADalimumab Dose Optimization in Rheumatoid Arthritis using (ADDORA) Adalimumab dose optimization in rheumatoid arthritis using therapeuticdrug monitoring (ADDORA): mult ... | Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D2E7 INN or Proposed INN: ADALIMUMAB Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D ... | Reade | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 267 | Phase 1;Phase 4 | Netherlands | ||
| 9 | ChiCTR1900025013 | 2019-08-08 | 2019-08-07 | Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis a ... | Effects of multiple dose use of tranexamic acid on blood loss and inflammatory factors after total knee arthroplasty in patients with rheumatoid arthritis Effects of multiple dose use of tranexamic acid on bloodloss and inflammatory factors after total kn ... | Total knee arthroplasty | group 1:Intravenous infusion of 1g of tranexamic acid at 3 hours after surgery ;group 2:Intravenous infusion of 1g of tranexamic acid at 3, 6, and 12 hours after surgery; group 1:Intravenous infusion of 1g of tranexamic acid at 3 hours after surgery ;group 2:Intravenous ... | Guanghua Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai University of Traditional Chinese Medicine Guanghua Hospital of Integrated Traditional Chinese Medicine and Western Medicine, Shanghai Universi ... | NULL | Recruiting | 50 | 75 | Both | group 1:52;group 2:52; | Phase 4 | China |
| 10 | ITMCTR1900002510 | 2019-08-08 | 2019-08-07 | Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis after total knee arthroplasty Clinical observation of multiple dose use of tranexamic acid in patients with rheumatoid arthritis a ... | Effects of multiple dose use of tranexamic acid on blood loss and inflammatory factors after total knee arthroplasty in patients with rheumatoid arthritis Effects of multiple dose use of tranexamic acid on bloodloss and inflammatory factors after total kn ... | Total knee arthroplasty | group 1:Intravenous infusion of 1g of tranexamic acid + 100 ml 3 hours after surgery, intravenous infusion of 100 ml of normal saline 6 and 12 hours after surgery.;group 2:Intravenous infusion of 1g of tranexamic acid + 100 ml of normal saline at 3, 6, and 12 hours after surgery; group 1:Intravenous infusion of 1g of tranexamic acid + 100 ml 3 hours after surgery, intravenous in ... | Guanghua Hospital, Shanghai University of Traditional Chinese Medicine | NULL | Recruiting | 50 | 75 | Both | group 1:38;group 2:38; | Phase 4 | China |